哮喘合剂治疗小儿哮喘寒哮型31例临床观察

Clinical observation of 31 infantile cold asthma treated with Xiaochuan Heji

目的观察哮喘合剂治疗哮喘寒哮型患儿的临床疗效。方法选择30例健康儿童作为正常组,同时选择符合哮喘寒哮型诊断标准的患儿60例,随机分为治疗组和对照组,治疗组31例口服哮喘合剂,对照组29例口服美普清。治疗7 d后,观察2组的临床疗效、临床症状消失时间及血白细胞介素(IL)-4,IL-17的变化情况。结果治疗组治愈率(83.87%)显著高于对照组(62.07%),2组比较差异有统计学意义(P<0.01)。治疗组在喘平、咳止、哮鸣音消失时间方面显著短于对照组,差异有统计学意义(P<0.05)。2组治疗前IL-4,IL-17比较差异无统计学意义(P>0.05);与同组治疗前比较,治疗后2组IL-4,IL-17均下降,差异有统计学意义(P<0.05);且治疗组下降幅度大于对照组,2组比较差异有统计学意义(P<0.05);治疗后,治疗组和对照组的IL-4,IL-17水平显著高于健康组(P<0.05)。结论哮喘合剂治疗哮喘寒哮型患儿临床疗效显著。

Objective To observe the clinical effect of infantile cold asthma treated with Xiaochuan Heji. Methods Selected 30 cases of healthy children as normal group, and 60 cases of infantile cold asthma were divided into two groups. The control group with 29 cases was given oral Meptin, while the therapy group was given oral Xiaoehuan Heji. After treated for 7 days, the disappearing time of clinical symptoms, clinical effect, changes of IL-4 and IL-17 were observed. Results The recovery rate of therapy group （83.87%） was much higher than that （62.07%） of control group with significant difference （P〈0.01）. The cough-stopping time and disappearing time wheezing rale in therapy group were much shorter than these of control group with significant difference （P〈0.05）. Before treatment, differences of IL-4 and IL-17 had no statistical significance （P〉0.05） ,after treatment,lL-4 and IL- 17 both dropped in two groups with significant difference （P〈0.05） ,the degree of improvement of therapy group was more than that of control group with significant difference （P〈0.05）. IL-4 and IL- 17 in two groups were much higher than that of normal group after treatment,there were significant differences （P〈0.05）. Conclusion Xiaochuan Heji can treat infantile cold asthma effectively, and IL-4 and IL-17 have a good influence on guiding function of clinical medication in onset.